Mar. 31 at 4:25 PM
$OLMA Olema seems to have a better drug than Roche had. Buyout in sight IMO.
Olema (Palazestrant/OP-1250): Designed as both a SERD and a Complete Estrogen Receptor Antagonist (CERAN). It is considered to have superior potency and superior exposure compared to Roche’s Giredestrant.
It’s either a buyout in the
$3B-
$4B, a major Home Run on Phase III for breast cancer with
$20B instant market cap or a Phase III failure with
$500M in cash to keep on working on existing other studies.
$30 to
$40 easy before OP-1250 results this autumn.
$XBI
